ABBV-400
Advanced histologically or cytologically confirmed solid tumors characterized by MET amplification
Elezanumab
Acute spinal cord injury
Venetoclax
- Chronic Lymphocytic Leukemia (CLL)
- Multiple Myeloma
- Acute Myeloid Leukemia (AML)
- Non-Hodgkin's Lymphoma
- Acute Lymphoblastic Leukemia (ALL)
- Amyloidosis
- Plasma Cell Leukemia
Upadacitinib oral solution
• Ulcerative colitis (UC)
• Crohn's disease (CD)
• Juvenile idiopathic arthritis (including sJIA, pJlA or JPsA)
• Rheumatoid Arthritis (RA)
• Psoriatic Arthritis (PsA)
• Axial Spondyloarthritis (axSpA)
• Non-radiographic Axial Spondyloarthritis (nr-axSpA)
• Giant Cell Arteritis (GCA)
• Systemic Lupus Erythematosus (SLE)
• Atopic dermatitis (AD)
• Alopecia Areata (AA)
• Non Segmental Vitiligo (NSV)
• Hidradenitis suppurativa (HS)
Mirvetuximab Soravtansine
Platinum-resistant, advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha (FRα) expression
Elezanumab –
Acute Spinal Cord Injury
EA Policies for Single Patient
ABBV-400
This program is designed to provide access to ABBV-400 prior to approval by the local regulatory agency. Availability will depend on the territory eligibility.
A medical doctor must decide whether the patient might potentially benefit from receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.
Criteria:
- The patient suffers from a serious or life-threatening illness or condition
- There are no other suitable treatment options
- The patient does not qualify for ongoing clinical trials
ClinicalTrials.gov URL: https://clinicaltrials.gov/study/NCT05982873
Venetoclax
This program is designed to provide access to Venetoclax prior to approval by the local regulatory agency. Availability will depend on the territory eligibility.
A medical doctor must decide whether the patient might potentially benefit from receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.
Criteria:
- The patient suffers from a serious or life-threatening illness or condition
- There are no other suitable treatment options
- The patient does not qualify for ongoing clinical trials
ClinicalTrials.gov URL: https://clinicaltrials.gov/study/NCT03123029
Upadacitinib oral solution
This program is designed to provide access to Upadacitinib oral solution prior to approval by the local regulatory agency. Availability will depend on the territory eligibility.
A medical doctor must decide whether the patient might potentially benefit from receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.
Criteria:
- The patient suffers from a serious or life-threatening illness or condition
- There are no other suitable treatment options
- The patient does not qualify for ongoing clinical trials
ClinicalTrials.gov URL: https://clinicaltrials.gov/study/NCT04159597
Mirvetuximab Soravtansine
This program is designed to provide access to Mirvetuximab Soravtansine prior to approval by the local regulatory agency. Availability will depend on the territory eligibility.
A medical doctor must decide whether the patient might potentially benefit from receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.
Criteria:
- The patient suffers from a serious or life-threatening illness or condition
- There are no other suitable treatment options
- The patient does not qualify for ongoing clinical trials
ClinicalTrials.gov URL: https://clinicaltrials.gov/study/NCT04209855